Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
2017 ◽
Vol 18
(7)
◽
pp. 874-886
◽
Keyword(s):
Phase 3
◽